Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid Antibody Syndrome: Is the Follow-Up Interval of 12 Weeks Instead of 6 Weeks Significantly Useful?
Table 1
Assessment of the clinical symptom positivity in the 59 patients with initial test positive on each combination of test item with respect to different follow-up interval.
Number of patients/number of patients with clinical symptoms (%)
Follow-up interval
Follow-up interval
6–12 weeks
More than 12 weeks
6–12 weeks
More than 12 weeks
Negative conversion (positive negative, )
Persistent positive (positive positive, )
LA confirm only ()
5/1 (20.0%)
0/0
2/1 (50.0%)
0/0
Anti-GPI only ()
1/0 (0.0%)
5/2 (40.0%)
3/2 (66.7%)
10/1 (10.0%)
ACA only ()
9/0 (0.0%)
4/1 (25.0%)
10/3 (30.0%)
3/1 (33.3%)
LA confirm + ACA ()
1/1 (100.0%)
0/0
1/1 (100.0%)
0/0
Anti-GPI + ACA ()
0/0
0/0
3/2 (66.7%)
1/1 (100.0%)
LA confirm + anti-GPI + ACA ()
0/0
0/0
0/0
1/1 (100.0%)
Totals ()
16/2 (12.5%)
9/3 (33.3%), = 0.230
19/9 (47.4%)
15/4 (26.7%), = 0.191
LA: lupus anticoagulants; GPI: glycoprotein-I; ACA: anti-cardiolipin antibody. values were obtained from Fisher’s exact test.
